Cite
MLA Citation
Raphael Schiffmann et al.. “Pegunigalsidase alfa, a novel PEGylated enzyme replacement therapy for Fabry disease, provides sustained plasma concentrations and favorable pharmacodynamics: A 1‐year Phase 1/2 clinical trial.” Journal of inherited metabolic disease, vol. 42, no. 3, 2019, pp. 534–544. http://access.bl.uk/ark:/81055/vdc_100081454994.0x00003b